Showing results (811-820 of 896) with videos related to

Sort By:
Pageof 90
European Urology Open Science|June 17, 2026
Corrigendum to "Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials" [Eur. Urol. Open Sci. 83 (2026) 133-141]Leo Bickley, Elisabeth E Fransen van de Putte, Luna van den Brink, et al.
Cell Reports|April 18, 2019
CD89 Is a Potent Innate Receptor for Bacteria and Mediates Host Protection from SepsisChristian de Tymowski, Nicholas Heming, Mario D T Correia, et al.
Lancet (London, England)|February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trialRobert J Motzer, Paul Russo, Viktor Grünwald, et al.
Science Translational Medicine|March 27, 2024
The gut microbiota posttranslationally modifies IgA1 in autoimmune glomerulonephritisPatrick J Gleeson, Nicolas Benech, Jonathan Chemouny, et al.
European Urology Oncology|August 19, 2025
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell CarcinomaCristiane D Bergerot, David Cella, Paulo G Bergerot, et al.
Targeted Oncology|September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 TrialRobert J Motzer, Paul Russo, Viktor Grünwald, et al.
Frontiers in Endocrinology|October 17, 2024
Policy for transitioning childhood-onset growth hormone deficiency from pediatric to adult endocrine care in BelgiumWillem Staels, Jean De Schepper, Marianne Becker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell CancerBhavna Oza, Tim Eisen, Eleni Frangou, et al.
Cancer Immunology Research|May 28, 2015
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell CarcinomaXian-De Liu, Anh Hoang, Lijun Zhou, et al.
Kidney International|December 24, 2019
Mast cell chymase protects against acute ischemic kidney injury by limiting neutrophil hyperactivation and recruitmentLydia Celia Madjene, Luca Danelli, Albert Dahdah, et al.
Pageof 90